STAT+: Pharmalittle: FDA declines to approve old antidepressant for Covid; U.S.-China trade fight may derail WTO Covid patent waiver

The FDA declined Monday to authorize fluvoxamine, a 30-year-old generic antidepressant, as a treatment for Covid-19.

Rise and shine, another busy day is on the way. However, this is also shaping up as a beautiful day, given the clear and sunny skies — and delicious breezes — enveloping the Pharmalot campus this morning. This calls for celebration with a cup of stimulation, and we are opening a new package of bourbon pecan for the occasion. As always, you are invited to join us. Meanwhile, the time has come to tackle the ever-growing to-do list. Sound familiar? So … here are some items of interest. Have a great day, everyone, and do keep in touch. …

The U.S. Food and Drug Administration declined Monday to authorize a 30-year-old generic antidepressant as a treatment for Covid-19, STAT reports. The move deals a major blow to a small group of doctors who have organized around the pill for months, arguing that it could provide a cheap and accessible way to prevent hospitalizations and death both in the U.S. and around the world. In an unusual two-page summary from an agency that does not generally disclose the reasoning behind rejections, the FDA maintained that the doctors failed to provide adequate evidence of effectiveness of the drug, called fluvoxamine.

Continue to STAT+ to read the full story…